EMA grants ODD to Sage Therapeutics’ SAGE-718 to treat Huntington’s disease
SAGE-718 is a first-in-class NMDA receptor positive allosteric modulator (PAM) as well as lead neuropsychiatric drug candidate. It is in development as a potential oral therapy for cognitive